Login Register Cart 0
Generic placeholder image

Cardiovascular & Hematological Disorders-Drug Targets

Editor-in-Chief

ISSN (Print): 1871-529X
ISSN (Online): 2212-4063

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Incidence of Restenosis Following Rapamycin or Paclitaxeleluting Stent in Coronary Stent Implantation

Author(s): Amir Shakarami*

Volume 21, Issue 3, 2021

Published on: 21 December, 2021

Page: [196 - 201] Pages: 6

DOI: 10.2174/1871529X21666211209115126

Price: $65

Abstract

Background: Coronary artery disease (CAD) is chiefly characterized by atherosclerosis and plaque formation in coronary arteries. The aim of this study was to evaluate the correlation of coronary anatomy as a predictor of restenosis and stent thrombosis in coronary artery disease (CAD) patients 5 years after percutaneous coronary intervention (PCI).

Methods: In this prospective study, 1070 patients with stent restenosis or stent thrombosis over past 5 years were enrolled. Coronary angiography was performed to evaluate coronary restenosis and stent thrombosis 5 years after PCI. Stent restenosis was defined as >50% angiographic in-stent lumen reduction. Stent thrombosis was defined as sudden complete occlusion of stent presenting with acute myocardial infarction in that territory. Demographic data, clinical features and anatomic factors were prospectively reviewed. Baseline, procedural, and post-procedural characteristics of patients were recorded for analysis.

Results: Among demographic characteristics, cardiovascular risk factors (hypertension and diabetes mellitus) and anatomic factors were predictive risk factors for restenosis/thrombosis, p=0.001. The most common site for stent restenosis was proximal to the mid part of the LAD artery, followed by RCA and LCX. A greater diameter of LCX, a greater angle of LM-LAD than LM-LCX and left dominancy increase the incidence of LAD stent restenosis/thrombosis. In this study, the least common restenosis/thrombosis rate in relation to the total number of PCI was in the Ramus intermedius artery.

Conclusion: The outcomes of the study indicated that anatomic factors can predict increased risk of restenosis among CAD patients who underwent PCI.

Keywords: Coronary artery disease (CAD), percutaneous coronary intervention (PCI), anatomy, angiography, restenosis, thrombosis.

« Previous Next »
Graphical Abstract

[1]
Trikalinos, T.A.; Alsheikh-Ali, A.A.; Tatsioni, A.; Nallamothu, B.K.; Kent, D.M. Percutaneous coronary interventions for non-acute coronary artery disease: a quantitative 20-year synopsis and a network meta-analysis. Lancet, 2009, 373(9667), 911-918.
[http://dx.doi.org/10.1016/S0140-6736(09)60319-6] [PMID: 19286090]
[2]
Assimes, T.L.; Roberts, R. Genetics: implications for prevention and management of coronary artery disease. J. Am. Coll. Cardiol., 2016, 68(25), 2797-2818.
[http://dx.doi.org/10.1016/j.jacc.2016.10.039] [PMID: 28007143]
[3]
Cui, K.; Lyu, S.; Song, X.; Yuan, F.; Xu, F.; Zhang, M.; Wang, W.; Zhang, D.; Dai, J. Drug-eluting balloon versus bare-mental stent and drug-eluting stent for de novo coronary artery disease: A systematic review and meta-analysis of 14 randomized controlled trials. PLoS One, 2017, 12(4), e0176365.
[http://dx.doi.org/10.1371/journal.pone.0176365] [PMID: 28445555]
[4]
Her, A-Y.; Shin, E-S. Current management of in-stent restenosis. Korean Circ. J., 2018, 48(5), 337-349.
[http://dx.doi.org/10.4070/kcj.2018.0103] [PMID: 29737639]
[5]
Gaubert, M.; Marlinge, M.; Alessandrini, M.; Laine, M.; Bonello, L.; Fromonot, J.; Cautela, J.; Thuny, F.; Barraud, J.; Mottola, G.; Rossi, P.; Fenouillet, E.; Ruf, J.; Guieu, R.; Paganelli, F. Uric acid levels are associated with endothelial dysfunction and severity of coronary atherosclerosis during a first episode of acute coronary syndrome. Purinergic Signal., 2018, 14(2), 191-199.
[http://dx.doi.org/10.1007/s11302-018-9604-9] [PMID: 29626320]
[6]
Wang, J-L.; Qin, Z.; Wang, Z-J.; Shi, D-M.; Liu, Y-Y.; Zhao, Y-X.; Yang, L.X.; Cheng, W.J.; Zhou, Y.J. New predictors of in-stent restenosis in patients with diabetes mellitus undergoing percutaneous coronary intervention with drug-eluting stent. J. Geriatr. Cardiol., 2018, 15(2), 137-145.
[PMID: 29662507]
[7]
Dalal, F.; Dalal, H.M.; Voukalis, C.; Gandhi, M.M. Management of patients after primary percutaneous coronary intervention for myocardial infarction. BMJ, 2017, 358, j3237.
[http://dx.doi.org/10.1136/bmj.j3237] [PMID: 28729460]
[8]
Kim, S.Y.; Guevara, J.P.; Kim, K.M.; Choi, H.K.; Heitjan, D.F.; Albert, D.A. Hyperuricemia and coronary heart disease: a systematic review and meta-analysis. Arthritis Care Res. (Hoboken), 2010, 62(2), 170-180.
[http://dx.doi.org/10.1002/acr.20065] [PMID: 20191515]
[9]
Aoki, J.; Kirtane, A.; Leon, M.B.; Dangas, G. Coronary artery aneurysms after drug-eluting stent implantation. JACC Cardiovasc. Interv., 2008, 1(1), 14-21.
[http://dx.doi.org/10.1016/j.jcin.2007.10.004] [PMID: 19393139]
[10]
Galkina, E.; Ley, K. Immune and inflammatory mechanisms of atherosclerosis (*). Annu. Rev. Immunol., 2009, 27, 165-197.
[http://dx.doi.org/10.1146/annurev.immunol.021908.132620] [PMID: 19302038]
[11]
Sukhija, R.; Aronow, W.S.; Sureddi, R.; Aleti, S.; Molavi, B.; Sachdeva, R.; Mehta, J.L. Predictors of in-stent restenosis and patient outcome after percutaneous coronary intervention in patients with diabetes mellitus. Am. J. Cardiol., 2007, 100(5), 777-780.
[http://dx.doi.org/10.1016/j.amjcard.2007.03.097] [PMID: 17719319]
[12]
Vranckx, P.; Valgimigli, M.; Jüni, P.; Hamm, C.; Steg, P.G.; Heg, D.; van Es, G.A.; McFadden, E.P.; Onuma, Y.; van Meijeren, C.; Chichareon, P.; Benit, E.; Möllmann, H.; Janssens, L.; Ferrario, M.; Moschovitis, A.; Zurakowski, A.; Dominici, M.; Van Geuns, R.J.; Huber, K.; Slagboom, T.; Serruys, P.W.; Windecker, S. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. Lancet, 2018, 392(10151), 940-949.
[http://dx.doi.org/10.1016/S0140-6736(18)31858-0] [PMID: 30166073]
[13]
Rodés-Cabau, J.; Masson, J-B.; Welsh, R.C.; Blanco, B.G.D.; Pelletier, M.; Webb, J.G.; Al-Qoofi, F.; Généreux, P.; Maluenda, G.; Thoenes, M.; Paradis, J-M.; Chamandi, C.; Serra, R.C.; Dumont, E.; Côté, M. Aspirin versus aspirin plus clopidogrel as antithrombotic treatment following transcatheter aortic valve replacement with a balloon-expandable valve: The ARTE (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) Randomized Clinical Trial. JACC Cardiovasc Interv., 2017, 10(13), 1357-1365.
[http://dx.doi.org/10.1016/j.jcin.2017.04.014] [PMID: 28527771]
[14]
Wang, Y.; Johnston, S.C. Rationale and design of a randomized, double-blind trial comparing the effects of a 3-month clopidogrel-aspirin regimen versus aspirin alone for the treatment of high-risk patients with acute nondisabling cerebrovascular event. Am. Heart J., 2010, 160(3), 380-386.e1.
[http://dx.doi.org/10.1016/j.ahj.2010.05.017] [PMID: 20826243]
[15]
Imai, K.; Okura, H.; Kume, T.; Yamada, R.; Miyamoto, Y.; Kawamoto, T.; Neishi, Y.; Watanabe, N.; Toyota, E.; Yoshida, K. C-reactive protein predicts non-target lesion revascularization and cardiac events following percutaneous coronary intervention in patients with angina pectoris. J. Cardiol., 2009, 53(3), 388-395.
[http://dx.doi.org/10.1016/j.jjcc.2009.01.005] [PMID: 19477381]
[16]
Xu, Y.L.; Li, J.J.; Xu, B.; Zhu, C.G.; Yang, Y.J.; Chen, J.L.; Qiao, S.B.; Yuan, J.Q.; Qin, X.W.; Ma, W.H.; Yao, M.; Liu, H.B.; Wu, Y.J.; Chen, J.; You, S.J.; Dai, J.; Xia, R.; Gao, R.L. Increased plasma C-reactive protein level predicts rapid progression of non-target atherosclerotic lesions in patients with stable angina after stenting. Chin. Med. J. (Engl.), 2011, 124(19), 3022-3029.
[PMID: 22040548]
[17]
Zairis, M.N.; Manousakis, S.J.; Stefanidis, A.S.; Vitalis, D.P.; Tsanis, E.M.; Hadjigeorgiou, S.M.; Fakiolas, C.N.; Pissimissis, E.G.; Olympios, C.D.; Foussas, S.G. C-reactive protein and rapidly progressive coronary artery disease-is there any relation? Clin. Cardiol., 2003, 26(2), 85-90.
[http://dx.doi.org/10.1002/clc.4960260208] [PMID: 12625599]
[18]
Nakachi, T.; Kosuge, M.; Hibi, K.; Ebina, T.; Hashiba, K.; Mitsuhashi, T.; Endo, M.; Umemura, S.; Kimura, K. C-reactive protein elevation and rapid angiographic progression of nonculprit lesion in patients with non-ST-segment elevation acute coronary syndrome. Circ. J., 2008, 72(12), 1953-1959.
[http://dx.doi.org/10.1253/circj.CJ-08-0185] [PMID: 18957790]
[19]
Gogo, P.B., Jr; Schneider, D.J.; Watkins, M.W.; Terrien, E.F.; Sobel, B.E.; Dauerman, H.L. Systemic inflammation after drug-eluting stent placement. J. Thromb. Thrombolysis, 2005, 19(2), 87-92.
[http://dx.doi.org/10.1007/s11239-005-1378-6] [PMID: 16052297]
[20]
Cheng, G.; Chang, F-J.; Wang, Y.; You, P-H.; Chen, H-C.; Han, W-Q.; Wang, J.W.; Zhong, N.E.; Min, Z.Q. Factors influencing stent restenosis after percutaneous coronary intervention in patients with coronary heart disease: a clinical trial based on 1-year follow-up. Med. Sci. Monit., 2019, 25, 240-247.
[http://dx.doi.org/10.12659/MSM.908692] [PMID: 30617247]
[21]
Watanabe, Y.; Takagi, K.; Naganuma, T.; Kawamoto, H.; Fujino, Y.; Ishiguro, H.; Tahara, S.; Kurita, N.; Hosawa, K.; Nakamura, S.; Nakamura, S. Independent predictors of in-stent restenosis after drug-eluting stent implantation for ostial right coronary artery lesions. Int. J. Cardiol., 2017, 240, 108-113.
[http://dx.doi.org/10.1016/j.ijcard.2017.04.083] [PMID: 28476515]
[22]
Cassese, S.; Byrne, R.A.; Tada, T.; Pinieck, S.; Joner, M.; Ibrahim, T.; King, L.A.; Fusaro, M.; Laugwitz, K.L.; Kastrati, A. Incidence and predictors of restenosis after coronary stenting in 10 004 patients with surveillance angiography. Heart, 2014, 100(2), 153-159.
[http://dx.doi.org/10.1136/heartjnl-2013-304933] [PMID: 24270744]

Rights & Permissions Print Cite
Article Metrics
19
2
1
© 2024 Bentham Science Publishers | Privacy Policy